+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Methicillin-Resistant Staphylococcus Aureus Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • PDF Icon

    Report

  • 200 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5748914

The development of novel targeted therapies and alternative treatment approaches to combat increasingly resistant strains

The Global Methicillin-Resistant Staphylococcus Aureus Drugs Market is estimated to be USD 1.87 Bn in 2023 and is expected to reach USD 2.49 Bn by 2028 growing at a CAGR of 5.85%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Methicillin-Resistant Staphylococcus Aureus Drugs Market is segmented based on Drug Class, MOA, Drug Origin, Route of Administration, Distribution Channels, and Geography.
  • By Drug Class, the market is classified into Cephalosporin, Folate Antagonist, Lipoglycopeptide, Lipopeptides, Oxazolidinone, and Tetracycline.
  • By MOA, the market is classified into Bactericidal Drugs and Bacteriostatic.
  • By Drug Origin, the market is classified into Semisynthetic and Synthetic Drugs.
  • By Route of Administration, the market is classified into Oral Administration and Parenteral Administration.
  • By Distribution Channels, the market is classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Melinta Therapeutics Inc, Merck & Co. Inc., Nabriva Therapeutics GmbH, Paratek Pharmaceuticals Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Methicillin-Resistant Staphylococcus Aureus Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increased Prevalence of Global Infections and Demand for Novel Therapies
4.1.2 Rise in Research Activities to Develop Novel MRSA Drugs
4.2 Restraints
4.2.1 Lack of Systematic Surveillance for MRSA Infection in Developing Countries
4.3 Opportunities
4.3.1 Increased Government Initiatives
4.3.2 Increasing Strategic Alliances and Investments
4.4 Challenges
4.4.1 Side Effects Associated with MRSA Drugs
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 SWOT Analysis
5.5 Impact of COVID-19
5.6 Impact of Economic Slowdown & Impending Recession
5.7 Ansoff Matrix Analysis
6 Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, By Drug Class
6.1 Introduction
6.2 Cephalosporin
6.3 Folate Antagonist
6.4 Lipoglycopeptide
6.5 Lipopeptides
6.6 Oxazolidinone
6.7 Tetracycline
7 Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, By MOA
7.1 Introduction
7.2 Bactericidal Drugs
7.3 Bacteriostatic
8 Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, By Drug Origin
8.1 Introduction
8.2 Semisynthetic
8.3 Synthetic Drugs
9 Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, By Route of Administration
9.1 Introduction
9.2 Oral Administration
9.3 Parenteral Administration
10 Global Methicillin-Resistant Staphylococcus Aureus Drugs Market, By Distribution Channels
10.1 Introduction
10.2 Hospital Pharmacies
10.3 Retail Pharmacies
10.4 Online Pharmacies
11 Americas' Methicillin-Resistant Staphylococcus Aureus Drugs Market
11.1 Introduction
11.2 Argentina
11.3 Brazil
11.4 Canada
11.5 Chile
11.6 Colombia
11.7 Mexico
11.8 Peru
11.9 United States
11.10 Rest of Americas
12 Europe's Methicillin-Resistant Staphylococcus Aureus Drugs Market
12.1 Introduction
12.2 Austria
12.3 Belgium
12.4 Denmark
12.5 Finland
12.6 France
12.7 Germany
12.8 Italy
12.9 Netherlands
12.10 Norway
12.11 Poland
12.12 Russia
12.13 Spain
12.14 Sweden
12.15 Switzerland
12.16 United Kingdom
12.17 Rest of Europe
13 Middle East and Africa's Methicillin-Resistant Staphylococcus Aureus Drugs Market
13.1 Introduction
13.2 Egypt
13.3 Israel
13.4 Qatar
13.5 Saudi Arabia
13.6 South Africa
13.7 United Arab Emirates
13.8 Rest of MEA
14 APAC's Methicillin-Resistant Staphylococcus Aureus Drugs Market
14.1 Introduction
14.2 Australia
14.3 Bangladesh
14.4 China
14.5 India
14.6 Indonesia
14.7 Japan
14.8 Malaysia
14.9 Philippines
14.10 Singapore
14.11 South Korea
14.12 Sri Lanka
14.13 Thailand
14.14 Taiwan
14.15 Rest of Asia-Pacific
15 Competitive Landscape
15.1 Competitive Quadrant
15.2 Market Share Analysis
15.3 Strategic Initiatives
15.3.1 M&A and Investments
15.3.2 Partnerships and Collaborations
15.3.3 Product Developments and Improvements
16 Company Profiles
16.1 AbbVie Inc.
16.2 Allergan PLC
16.3 AmpliPhi Biosciences Corp.
16.4 Armata Pharmaceuticals Inc.
16.5 AstraZeneca PLC
16.6 Basilea Pharmaceutica Ltd.
16.7 Cumberland Pharmaceuticals Inc.
16.8 DE Holdco Inc.
16.9 Debiopharm International S.A.
16.10 F. Hoffmann-La Roche AG
16.11 Melinta Therapeutics Inc.
16.12 Merck & Co. Inc.
16.13 Nabriva T herapeutics GmbH
16.14 Novartis Ag
16.15 Paratek Pharmaceuticals Inc.
16.16 Pfizer Inc.
16.17 Sanofi S.A.
16.18 Teva Pharmaceutical Industries Ltd.
16.19 Theravance Biopharma
17 Appendix
17.1 Questionnaire

Companies Mentioned

  • AbbVie Inc.
  • Allergan PLC
  • AmpliPhi Biosciences Corp.
  • Armata Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Cumberland Pharmaceuticals Inc.
  • DE Holdco Inc.
  • Debiopharm International S.A.
  • F. Hoffmann-La Roche AG
  • Melinta Therapeutics Inc.
  • Merck & Co. Inc.
  • Nabriva T herapeutics GmbH
  • Novartis Ag
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma